A cautionary note on recall vaccination in ex-COVID-19 subjects

Introduction

Currently approved COVID-19 vaccines based on mRNA ^1–3 or adenovirus ⁴ require a first jab followed by recall immunization. The impact of previous exposure to SARS-CoV-2 on immune response elicited the vaccines has not been assessed.

Methods

We tested the antibody response developed after the first dose of the mRNA based vaccine encoding the SARS-CoV-2 full-length spike protein (BNT162b2)¹ in 124 healthcare professionals of which 57 had a previous history of COVID-19 (ExCOVID) (Table 1), as part of an observational study (clinicaltrial.gov NCT04387929) conducted at Istituto Clinico Humanitas in which healthcare professionals were followed for serology and for any occurring COVID-19 related symptoms every three months⁵. We recorded the antibody response to Spike 1/2 with a quantitative test (Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Italy) which allowed us to evaluate even large amounts of plasma IgG. To predict the IgG response for SARS-COV-2 vaccine, a multivariate Linear Regression (LR) model with l2 regularization (also known as Ridge Regression) was developed. Numerical variables were standardized (z-score algorithm) and the target variable was log transformed due to right asymmetry of the distribution. The subjects without the serological analysis before vaccination were excluded from this analysis (n=11). The final number of subjects analyzed in LR was 113.

Results

As shown in Fig.1A-B ExCOVID individuals had a much higher antibody response after the first dose of vaccine than naïve subjects (p<0.0001), regardless of when they developed the COVID-19. They displayed an exponential increase of anti-Spike 1/2 antibody response within 7-15 days after the first dose of vaccine. The pre-vaccine antibody amount of the ExCOVID population was on average 44.+/-37.7 while that after the vaccine was 1055.7+/-1004.2 (p<0.0001) (Table 1), with higher levels in symptomatic ExCOVID (Fig. 1C, p=0.028).

• Download figure
• Open in new tab

Figure 1: ExCOVID subjects increase exponentially anti-Spike 1/2 IgG levels after the first dose of vaccine.

A, anti-Spike 1/2 IgG plasma levels in healthy (n=67) and ExCOVID individuals (n=57) measured after the first dose of vaccine. B, anti-Spike 1/2 IgG plasma levels in healthy (n=67) and ExCOVID individuals (n=46) measured before and after the first dose of vaccine. C, anti-Spike 1/2 IgG plasma levels in asymptomatic / paucisymptomatic (n=15) and in symptomatic (n=42) ExCOVID individuals measured after the first dose of vaccine. D, Multivariate linear regression coefficients for the most significant variables (p<0.05). Dot points represent the mean values and the lines the 95% CI.

The box plots (A, C) show the interquartile range, the horizontal lines show the median values and the whiskers indicate the minimum-to-maximum range. P values were determined using two-tailed unpaired Mann–Whitney test (A) or two-tailed Wilcoxon matched-pairs signed rank test (B) or two-tailed unpaired Kolmogorov-Smirnov test (C).

We investigated the relationship between the amount of IgG after vaccination with COVID-19, sex, age and symptoms related to disease. The final LR shows a good prediction of the target variable (R²=0.88, F-statistic = 39.18, p-value<0.001) and the most significant features were history of COVID-19 (1.48, 95% CI 1.07-1.93), the value of IgG before vaccination (0.87, 95% CI 0.59-1.13), the difference between the date of vaccination and the date of serology post-vax (0.87, 95% CI 0.65-1.03), and age (−0.13, 95% CI −0.24-−0.001) as well as COVID-19 related symptoms: gastrointestinal disorders (0.59, 95% CI 0.16-0.97), anosmia/dysgeusia (0.50, 95% CI 0.14-0.87), tachycardia (0.26, 95% CI 0.02-0.60) and sore throat (−0.35, 95% CI −0.53-−0.11) (Fig. 1D, Suppl. Table1).

Discussion

The antibody response of ExCOVID patients depends on the IgG pre-vaccine titer and on the symptoms that they developed during the disorder, with anosmia/dysgeusia and gastrointestinal disorders being the most significantly positively correlated in the LR, while sore throat was negatively correlated because 45% non-COVID individuals reported it. Young subjects had a higher antibody response. We previously observed that anosmia/dysgeusia was associated with an increase of antibodies over time, independently of vaccination (Levi et al. submitted). Thus, one vaccine dose is sufficient to induce a good antibody response in ExCOVID subjects and poses caution for a second dose: over stimulation with high amount of antigens could switch-off the immune response due to antigen exhaustion, which occurs in response to several viruses (reviewed in⁶). Alternatively, overactivation of the immune response may drive the development of low-affinity antibodies for SARS-CoV-2 which may foster an antibody dependent enhancement (ADE) reaction when re-exposed to the virus (reviewed in⁷). These results question whether a second shot in ExCOVID subjects is indeed required and suggest to post-pone it while monitoring antibody response longevity. At a time of vaccine scarcity, these findings may have public health implications.